Appeals court upholds Gore win over St. Jude Medical
June 9, 2014 by Brad Perriello
A federal appeals court today upheld a win for W.L. Gore & Assoc. in a patent war with St. Jude Medical over heart defect repair technology.
AGA Medical sued Gore in 2010, months before St. Jude paid $1.03 billion to acquire AGA, accusing Gore of violating a patent with its Helex septal occluder. The device is an implant designed to treat a structural heart defects and competes with the Amplatzer device made by AGA/St. Jude. Read more
Independent legal panel rejects Infuse allegations in Medtronic shareholder suits
June 10, 2014 by Brad Perriello
A federal appeals court today upheld a win for W.L. Gore & Assoc. in a patent war with St. Jude Medical over heart defect repair technology.
AGA Medical sued Gore in 2010, months before St. Jude paid $1.03 billion to acquire AGA, accusing Gore of violating a patent with its Helex septal occluder. The device is an implant designed to treat a structural heart defects and competes with the Amplatzer device made by AGA/St. Jude. Read more
Judge dismisses Anulex from Xclose off-label lawsuit
June 10, 2014 by Brad Perriello
A federal judge last week dismissed Anulex Technologies from a lawsuit alleging unfair & deceptive trade practices for alleged off-label promotion of its Xclose soft tissue repair device.
Bennie Evans sued Anulex, his back surgeon and the doctor’s medical practice in 2010, alleging claims of negligent misrepresentation, fraud, unfair and deceptive trade practices, and breach of implied warranty. Read more
Appeals court upholds Abiomed win in shareholder's class action
June 11, 2014 by Brad Perriello
Abiomed held on to its win in a shareholder’s lawsuit filed against it in 2013 when a federal appeals court yesterday upheld a lower court’s decision to dismiss the case.
Plaintiff Marta Bryceland filed a shareholder derivative lawsuit in the U.S. District Court for Massachusetts, accusing chairman, president & CEO Michael Minogue and the rest of the company’s directors of issuing falsely rosy statements to artificially inflate its share price, despite knowing of a U.S. Justice Dept. investigation and a pair of warning letters from the FDA. Read more
Convicted ex-Heart Tronics CEO won't get a retrial, judge rules
June 11, 2014 by Arezu Sarvestani
A California District Judge harshly refused former Signalife and Heart Tronics CEO Mitchell Stein’s motion for a retrial, taking offense to the request itself.
Stein was convicted in May 2013 of 14 charges of fraudulently inflating share prices for heart monitoring devices maker Signalife (later Heart Tronics). Federal prosecutors called for a $5.4 million fine to account for Stein’s ill-gotten gains as well as those of his former chauffeur and co-conspirator. Read more
